Innovation Grants to Nurture Initial Translational Efforts (IGNITE): Neurotherapeutic Agent Characterization and In vivo Efficacy Studies (R61/R33 Clinical Trial Not Allowed)

This opportunity provides funding to conduct pharmacodynamic, pharmacokinetic, and in vivo efficacy studies to demonstrate that proposed therapeutic agent(s) have sufficient biological activity to warrant further development to treat neurological or neuromuscular disorders. The funding is part of the Innovation Grants to Nurture Initial Translational Efforts (IGNITE) to advance projects to the point where they can meet the entry criteria for the Blueprint Neurotherapeutics Network or other translational programs. Key aspects of this opportunity include: • The funding will support the development of therapeutic agents, including small molecules, biologics, or biotechnology-derived products. • The opportunity is open to various types of applicants, including non-profits, small businesses, and institutions of higher education. • The application deadline is October 20, 2027. • The funding instrument for this opportunity is a grant.